Free tool
FAERS Monitor: Clinolipid 20%
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204508 or its brand name (Clinolipid 20%, Olive Oil, Soybean Oil). Reports on generic versions are filed under their own applications.
Reports
32
Serious
15
47% of reports
Hospitalization
5
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- liver function test increased5
- flushing4
- nausea4
- blood alkaline phosphatase increased3
- drug ineffective3
- pruritus3
- urticaria3
- alanine aminotransferase increased2
- aspartate aminotransferase increased2
- back pain2
- blood triglycerides increased2
- death2
- dyspnoea2
- jaundice2
- product label confusion2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 4 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 7 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 5 |
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,127 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product label confusion | 2 | 225.6 | 59.0 | 251 |
| liver function test increasedSignal | 5 | 153.1 | 68.4 | 612 |
| blood alkaline phosphatase increasedSignal | 3 | 79.5 | 27.1 | 161 |
| blood triglycerides increased | 2 | 74.4 | 19.4 | 81 |
| jaundice | 2 | 48.9 | 12.8 | 52 |
| flushingSignal | 4 | 25.9 | 10.3 | 73 |
| aspartate aminotransferase increased | 2 | 24.8 | 6.5 | 25 |
| alanine aminotransferase increased | 2 | 21.4 | 5.6 | 21 |
| urticariaSignal | 3 | 11.8 | 4.0 | 20 |
| back pain | 2 | 5.7 | 1.5 | 4 |
| pruritusSignal | 3 | 5.1 | 1.7 | 6 |
| nauseaSignal | 4 | 3.3 | 1.3 | 5 |
| dyspnoea | 2 | 2.3 | 0.6 | 0 |
| death | 2 | 1.5 | 0.4 | 0 |
| drug ineffective | 3 | 1.5 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.